AstraZeneca and Merck in Anticancer Collaboration
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 6 (Table of Contents)
Published: 17 Jun-2009
DOI: 10.3833/pdr.v2009.i6.1122 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
AstraZeneca and Merck & Co have entered into a collaborative agreement to develop two investigational anticancer compounds, MK-2206 from Merck’s portfolio and AZD6244 (ARRY-886) from the AstraZeneca stable...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS